Drug - Publications - Faculty & Research - Harvard Business School

Filter Results: (991)

Filter Results: (991)

Show Results For

← Page 24 of 991 Results →

January 2021
Case

Value-Based Insurance Design at Onex

By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal

The operating executives of Health and Benefits for Onex Partners, Megan Jackson Frye and Sam Camens, faced a challenge: Healthcare costs for employees of Onex’s portfolio companies were continuing to rise above the consumer price index, reflecting broader trends... View Details

Web

Faculty & Advisors | MBA

Underscore VC, she invested in fast growing B2B software startups, including life sciences tech products used by leading biopharma companies across the drug development cycle from R&D to commercial stages. She began her career at Michael... View Details

Article

Overturning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization

By: Lucy Chen, Richard G. Frank and Haiden A. Huskamp

In late 2020, the Supreme Court began hearing a case challenging the Affordable Care Act (ACA), which led to coverage gains for many low-income, reproductive-age women. To explore potential implications of a full ACA repeal for this population, we examined gains... View Details

Keywords: Medicaid; Women's Health; Health Insurance; Health Care and Treatment; Gender; Insurance; Poverty; Health Industry; United States

22 Apr 2009
Working Paper Summaries

Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location

Keywords: by Arthur Daemmrich; Pharmaceutical

September 2023 (Revised April 2024)
Case

Atomwise: Strategic Opportunities in AI for Pharma

By: Satish Tadikonda

Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details

Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Pharmaceutical Industry

November 2007
Case

Antegren: A Beacon of Hope

By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann

The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details

Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Pharmaceutical Industry

September–October 2020
Article

The Past, Present, and (Near) Future of Gene Therapy and Gene Editing

By: Julia Pian, Amitabh Chandra and Ariel Dora Stern

Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details

Keywords: Gene Therapy; Gene Editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change

Find at Harvard

January 2007 (Revised August 2008)
Case

NatuRi Corporation

By: Robert F. Higgins and Virginia Fuller

NatuRi Corporation was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from the byproducts of rice bran oil production. With operations split between Chennai, India and Boston, Massachusetts, NatuRi faced several challenges,... View Details

Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Venture Capital; Equity; Investment Funds; Growth and Development Strategy; Chennai; Boston

2020
Working Paper

What Can Economics Say About Alzheimer's Disease?

By: Amitabh Chandra, Courtney Coile and Corina Mommaerts

Alzheimer’s Disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. While there is overlap with the economics of aging, the defining features of the... View Details

Keywords: Health Disorders; Health Care and Treatment; Economics

2016
Working Paper

Standardized Color in the Food Industry: The Co-Creation of the Food Coloring Business in the United States, 1870–1940

By: Ai Hisano

This working paper examines how, starting in the 1870s, food manufacturers in the United States began to use standardized color, achieved by synthetic dyes, as part of their marketing strategies. Food manufacturers along with dye makers and regulators co-created the... View Details

Keywords: Food; Supply and Industry; Manufacturing Industry; Food and Beverage Industry; United States

27 Jun 2019
News

Long-Term Investing, Short-Term Thinking

September 2024
Case

Myeloma Investment Fund

By: Kyle Myers and Scott Sawaya

This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.

The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details

Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Biotechnology Industry; Pharmaceutical Industry

05 Sep 2023
Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

In the 1990s, after drugmaker Eli Lilly spent more than a decade and millions of dollars developing the new drug Alimta to treat lung cancer, the medication came up short in effectively treating cancer in expanded trials. While the... View Details

Keywords: by Michael Blanding

January 2001 (Revised July 2003)
Case

Pharmacyclics: Financing Research & Development

By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia

Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details

Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Medical Devices and Supplies Industry; Pharmaceutical Industry; Health Industry

March 2014 (Revised November 2020)
Case

The Novartis Malaria Initiative

By: Michael Chu, Vincent Marie Dessain and Emilie Billaud

The Novartis Malaria Initiative was designed, as a result of a precedent–setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria—"at no profit"—for public health systems. What had begun as an exemplary act of... View Details

Keywords: Health Care and Treatment; Product Marketing; Corporate Social Responsibility and Impact; Social Enterprise; Pharmaceutical Industry; Switzerland; Africa; Nigeria

2024
Article

Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior

By: Olivia Zhao and Anna D Sinaiko

High out-of-pocket (OOP) prices for prescription drugs create financial difficulties for patients, and cost-related underuse of medications can adversely patient health. Simultaneously, many physicians report a willingness to address affordability concerns with... View Details

Keywords: Price; Health Care and Treatment; Communication Technology; Technology Adoption; Customer Focus and Relationships; Health Industry

Register to Read

October 2024
Case

Parexel: Scaling Up and Industry Dynamics

By: Regina E. Herzlinger and Ben Creo

Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details

Keywords: Research; Innovation and Invention; Business Model; Transformation; Globalization; Information Technology; Competitive Advantage; Pharmaceutical Industry

April 2009 (Revised May 2010)
Case

Partners In Health: HIV Care in Rwanda

By: Michael E. Porter, Scott S. Lee, Joseph Rhatigan and Jim Yong Kim

In 2005, Partners in Health (PIH) was invited by the Rwandan Ministry of Health to assume responsibility for the management of public health care in two rural districts in Eastern Rwanda and create an HIV treatment program at these sites. PIH successfully implemented a... View Details

Keywords: Developing Countries and Economies; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Service Delivery; Nonprofit Organizations; Expansion; Health Industry; Rwanda

June 2002 (Revised November 2005)
Case

Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa

By: Debora L. Spar

In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a... View Details

Keywords: Patents; Health Pandemics; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Africa

September 2007
Article

Investigative Negotiation

By: Deepak Malhotra and Max H. Bazerman

This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into... View Details

Keywords: Knowledge Acquisition; Knowledge Use and Leverage; Negotiation Process; Negotiation Tactics; Motivation and Incentives; Perspective; Pharmaceutical Industry

Find at Harvard

←
24
25
…
49
50
→